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Abstract Recent advances in nanotechnology have enabled
the development of nanoscale sensors that outperform
conventional biosensors. This review summarizes the nano-
scale biosensors that use aptamers as molecular recognition
elements. The advantages of aptamers over antibodies as
sensors are highlighted. These advantages are especially
apparent with electrical sensors such as electrochemical
sensors or those using field-effect transistors.
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Introduction
With the completion of the Human Genome Project, we have
a better understanding of disease-related biomaterials such as
DNA, RNA, proteins and small biological molecules. Such
knowledge can impact strongly on human health, because the
identification of a disease-specific marker at an early stage of
a disease can greatly improve the clinical success rate, and
improve disease-related mortality. For early detection of
disease, it is necessary to locate minute amounts of disease-
related proteins, peptides or other small molecules in a
patient’s bloodstream or body fluid. Nanotechnology com-
bined with biotechnology is expected to provide paradigm-
breaking solutions in this area, as these technologies are
extremely sensitive [1]. Already, nanoscale materials such as
quantum dots [2] and metallic nanoparticles [3, 4], as well as
nanodevices such as the nanocantilever [5], and nano field-
effect transistors (FETs) [6–9] show potential for detecting
tiny molecular signals.
In this review, we concentrate on nanoscale electrical
biosensors with aptamers as molecular recognition ele-
ments. Biosensors are devices that can be used to detect the
presence of a target analyte. As shown in Fig. 1, biosensors
are built up from a sample delivery component, a molecular
recognition subsystem, a transducer changing the binding
or reaction of target molecules into a measurable physical
signal (mass, charge, heat or light) and a signal-processing
unit. We are particularly interested here in electrical
transducers, because they provide the most promising
solutions for point-of-care disease detection. Biosensors
using electrical transducers are rapid and convenient, and
they do not require heavy optical instruments or expensive
measuring devices.
Aptamers as molecular recognition elements
For the highly sensitive detection of a target analyte, the
selectivity of the recognition element is vital in sensor
performance. Until recently, immunosensors using anti-
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body–antigen recognition were employed for biodetection.
However, highly sensitive and stable biosensors may use
different recognition elements. In the 1980s, functional
nucleic acids that can specifically bind and regulate viral or
celluar proteins with high affinity were discovered [10].
The major breakthrough for functional nucleic acids
occurred in 1990. First, the presence of small functional
RNA molecules (TAR aptamers) that can inhibit viral
replication [11] was revealed; they can effectively bind and
inhibit the activity of viral protein, thereby raising the
possibility that they may be used as therapeutic agents. In
the second study in 1990, Tuerk and Gold [12] established
the in vitro screening process termed "systematic evolution
of ligand by exponential enrichment" (SELEX), to identify
the RNA ligands with affinity for T4 DNA polymerase and
various organic dyes [12]. Such nucleic acids were termed
"aptamers" [from the Latin aptus (fit or appropriate)] by
Ellington and Szostak [13].
The SELEX process is a technique for screening a very
large library of oligonucleotides with random sequences by
iterative cycles of selection and amplification. Figure 2
shows a schematic diagram of the SELEX process [14].
The starting pool must be large enough to generate a high
probability of producing a desired aptamer (normally
around 1015 different sequences). The initial library of
random-sequence oligonucleotides, which is obtained
through combinatorial chemical synthesis, is incubated
with a target of interest. Oligonucleotides showing affinity
Fig. 2 The systematic evolution of ligand by exponential enrichment (SELEX) process [14]
Fig. 1 A biosensor. MIP
molecularly imprinted polymer
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for the target are partitioned by affinity chromatography or
filtration, and then amplified by PCR (for DNA libraries) or
reverse transcription PCR (for RNA libraries) to create a
new pool enriched in those oligonucleotides having a
higher affinity for the target. As this cycle of selection
and amplification is repeated, the abundance of the high-
affinity oligonucleotides increases exponentially. Negative
selection and counterselection are often employed in order
to remove aptamers which bind to supports and molecules
similar to the target, respectively. Typically after eight to 15
cycles, cloning and sequencing of the enriched library are
carried out, revealing the sequence of oligonucleotides
highly specific to the target. Once the sequence information
has been obtained, the desired aptamer can be readily
produced by chemical synthesis. For a given target
molecule, DNA aptamers and RNA aptamers can be
generated. However, they are quite different in sequence
and three-dimensional structure since DNA lacks the 2′
hydroxyl group of the RNA. For example, both the DNA
version of the RNA aptamer for ATP and the RNA version
of the DNA aptamer for ATP do not recognize ATP [15].
In Table 1, we summarize the advantages of aptamers
over antibodies and the yellow-colored rows detail special
advantages of aptamers as recognition elements [16]. First,
aptamers possess high target affinity. It has been generally
recognized that aptamer affinity is comparable to or even
higher than that of antibodies, even though this is not
always true. Unlike antibodies, aptamers can distinguish
between targets even if the targets are in the same family.
For example, anti-caffeine aptamers have lower affinity (by
a factor of 104) for theophylline, despite the two com-
pounds differing by only a single methyl group [17].
Because aptamers are selected using an in vitro selection
process (SELEX), they are cost-effective, have uniform
activity, and antitoxin aptamers can be readily synthesized.
Antitoxin antibodies are more difficult to prepare, since
they are cultured in animal cells. The immobilization of the
recognition element can be crucial in biosensors, and this is
easier with aptamers than with antibodies, because chemical
modification of nucleic acids is simple and straightforward
compared with that of antibodies. One of the biggest
advantages of aptamers lies in their high stability. Being
nucleic acids, aptamers are highly stable, and therefore have
unlimited shelf lives. Also, because aptamers can undergo
reversible changes of conformation with variations in
temperature or salt concentration, aptamer-based sensors
are potentially recyclable. The major limitation of aptamers
(especially RNA aptamers) as molecular recognition ele-
ments is degradation by nucleases. However, it was shown
that the problem can be overcome through chemical
modifications of the sugar at the 2′-position [18] or use of
mirror-image analogs [19]. Recently chemically modified
nucleic acid aptamers for in vitro selections have been
reviewed [20].
Table 1 Advantages of
aptamers over antibodies [16] Aptamers Antibodies 
Affinity Low nM–pM Low nM–pM 
Specificity High 
Production In vitro chemical process In vivo biological system 
Target range 
Wide: ions, small organic 





Batch to batch 
variation 
Little or no Significant 
Chemical 
modification 




Shelf-life Unlimited Limited 
High
Irreversible
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As aptamers show high target affinity and high target
specificity, they can be used as therapeutic agents, in affinity
columns and as recognition elements in sensors detecting a
wide range of targets. There are virtually no limits of targets for
aptamers; small molecules [14], proteins [15] and antibiotics
[21]. The first use of an aptamer as a molecular recognition
element in sensors was reported in 1996, when fluorescent-
tagged aptamers were employed for optical detection of human
neutrophil elastase [22]. Since then, various transducers
employing aptamers for recognition have been reported.
These include the quartz crystal microbalance [23], the surface
plasmon resonance technique [24], evanescent-wave-induced
fluorescence [25], microcantilevers [26], electrochemical
sensors [27–35] and FETs fabricated with single-walled
carbon nanotubes (SWNTs) [36, 37]. In this review, we
summarize recent advances in electrochemical and FET types
of aptamer sensors, focusing on the high sensitivity and
recyclability of the aptamer-containing devices.
Electrical aptamer sensors
Electrochemical aptamer sensors
Typical electrochemical sensors operate by reacting with an
analyte of interest and producing an electrical signal
proportional to the analyte concentration. Many papers
have reported the fabrication of electrochemical aptamer
sensors where specific binding of an analyte to an aptamer
on an electrode can produce an electrical signal [27–35].
Some authors use sandwich assays, employing a secondary
aptamer for signal enhancement [28, 29]. However, a
technique that is label-free and fast in response is favored
especially for electrical types of biosensors. A difficulty
with sandwich assays has recently been removed by Xiao
et al. [31], who developed a “signal-on” architecture.
Earlier electrochemical aptamer sensors used a “signal-
off” architecture [30], in which the binding of the target
analyte resulted in a decrease in the signal. In such cases,
no more than 100% of the signal can be suppressed by
target binding, and hence the dynamic range of the sensor is
limited. Also, it is difficult to distinguish a real binding
event from a false signal originating from contaminants or
sensor degradation. To fabricate the signal-on electrochem-
ical aptamer sensor, Xiao et al. introduced a short DNA
sequence tagged with methylene blue (MB) that can
hybridize with an aptamer. A single-stranded DNA
aptamer, which binds to thrombin, was chosen as a model
system. Thrombin is a proteolytic enzyme which facilitates
blood clotting by converting fibrinogen into fibrin and is
also regarded as a tumor marker in the diagnosis of
pulmonary metastasis [38]. Figure 3 shows a schematic
diagram of the signal-on aptamer sensor. As shown, the
sensor is constructed by immobilizing a thiolated thrombin
aptamer to a gold electrode, and an MB-tagged partially
complementary DNA is added to form a double-stranded
complex. In this configuration, owing to the large persis-
tence length of double-stranded DNA, the MB moiety is far
away from the sensor surface, and only a small Faradaic
current is observed. The persistence length, defined as the
distance over which the direction of a polymer segment
persists, provides a measure of elasticity in polymer chains.
In the case of double-stranded DNA, the persistence length
is about 50 nm, or 150 bp [39]. Since the thrombin aptamer
is much shorter than 150 bp [40] (the recognition part is
only 15 bp in length), the complex would be in a “standing”
position. When thrombin is introduced to such a complex,
the thrombin aptamer binds to thrombin, and the MB-
tagged single-stranded DNA approaches the electrode
surface, improving the electron transfer with an increase
of current. The persistence length of a single-stranded DNA
is 1.5 nm in 2 M NaCl solution, and 3 nm in 25 mM NaCl
solution [41].
In the work of Xiao et al., a threefold signal gain was
observed with 260 nM thrombin, while only a 40% signal
decrease was observed using a signal-off sensor. The
detection limit of the sensor thus rose to 3 nM as shown
in Fig. 4. Such a high sensitivity is comparable even with
that given by sensors using amplification by labeling [28,
29] or optical sensors using evanescent-wave-induced
fluorescence anisotropy [25]. Table 2 summarizes the
electrochemical aptamer sensors available for thrombin.
Fig. 3 Thrombin binding with an
engineered aptamer. MB methy-
lene blue. (Reprinted with permis-
sion from [31], copyright 2005
American Chemical Society)
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Owing to the unique three-dimensional structure of an
aptamer, it is not even necessary to use "holding" DNA
sequences. Baker et al. [34] reported the rapid, label-free
detection of cocaine in both adulterated samples and
biological fluid. The cocaine aptamer engineered by
Stojanovic et al. [42] was used in this work. This aptamer
is thought to form a partially unfolded structure, with only
one of its three double-stranded stems intact, when target
molecules are absent. In the presence of target, the aptamer
folds into the cocaine-binding three-way junction structure
of Fig. 5a. With this unique approach, Baker et al. reported
the detection of 500 μM cocaine in biological fluid, even
when contaminants were present. The ability to detect
cocaine in undiluted biological fluids (blood, for example)
is crucial for simple forensic detection technology. The
binding of small molecules to an aptamer is highly
reversible, so it is possible to regenerate the sensor. Baker
et al. [34] could regenerate the sensor to a degree of 99% by
simply washing a used sensor with buffer.
Regeneration of an aptamer sensor is also possible after
protein binding. Lai et al. [35] reported the detection of
picomolar levels of platelet-derived growth factor (PDGF)
directly in blood serum. PDGF is a protein that regulates
cell growth and division, and is very important for blood
vessel formation (angiogenesis). While generally undetect-
able in normal cells, PDGF is overexpressed in a variety of
disease such as atherosclerosis, and human tumors includ-
ing sarcomas and glioblastomas [14, 43]. As shown in
Fig. 5b, specific binding of PDGF to the aptamer decreases
the distance between MB and the electrode and conse-
Table 2 The detection limits of an electrochemical aptamer sensor for thrombin
Detection limit Characteristics Reference
1 3 nM Uses an MB-tagged "holding" DNA sequence [31]
2 80 nM/3.5 nM Peroxidase-labeled thrombin gives an 80 nM detection limit. Biotin-labeled aptamer with horse
radish peroxidase labeled streptavidin gives a detection limit of 3.5 nM
[27]
3 1 μM Sandwich assay using two aptamers with different binding sites. Secondary aptamer labeled with
glucose dehydrogenase
[28]
4 10 nM Same as for 3, but pyrroquinoline quinine glucose dehydrogenase is used for labeling [29]
5 6.4 nM MB-tagged thrombin aptamer (signal-off sensor) [30]
6 0.1–0.15 nM Thrombin aptamer with ferrocene moiety (square-wave voltametry or chronopotetiometry used for
the measurement)
[32]
7 11 nM MB-intercalated thrombin aptamer [25]
MB methylene blue
Fig. 4 Electrochemical signal from the signal-on aptamer sensor. (Reprinted with permission from [31], copyright 2005 American Chemical Society)
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quently increases the electrical signal. The sensor could be
also regenerated by 4-min incubation in 10% (w/v) sodium
dodecyl sulfate.
In this section, we have shown that engineered aptamers,
employed as recognition elements in electrochemical trans-
ducers, can greatly improve sensor performance. It is an
advantage of aptamers over antibodies that aptamers can be
engineered to either enhance or activate signals. Recently,
aptazymes (aptamers with catalytic activities) have been
reported, which combine an enzymatic role with a
recognition function [44]. Carefully designed aptazymes
can be developed as sensors that do not require labeling. An
electronic (electrochemical) sensor approach with carefully
designed aptamers offer potential for highly sensitive,
selective and reusable sensor platforms.
Aptamer sensors with carbon nanotube field-effect
transistor transducers
Since the first report on the biosensing ability of Si
nanowire in 2001 [45] and the development of the chemical
sensor operation of carbon nanotubes in 2000 [46],
extensive research efforts have been initiated aimed at
developing nanotube-based or nanowire-based sensors.
Owing to the extremely large surface-to-volume ratio of
one-dimensional nanostructures, it is possible to develop
sensors with exquisite sensitivity. This is especially true in
the case of carbon nanotubes, where all constituent atoms
are at the surface. Any small disturbance of or adsorption to
the surface could result in a large change in electrical
conductance. Already, biosensors fabricated with semicon-
ducting nanowires or nanotubes have been used as sensors
that can detect a single virus [6], small molecules [47] or
minute amounts of proteins in solution [7–9].
FET sensors measure a change in the surface potential
occurring during the binding between an analyte and a
recognition element. Figure 6 shows a schematic diagram
of the working principle of carbon-nanotube-based FET
sensors. FET sensors “feel” the charges when target
molecules bind with probe molecules immobilized on the
sensor surfaces. Such an effect is often referred to as an
“electrostatic gating effect” since the bound target mole-
cules behave as an additional gate electrode. In the case of
carbon nanotubes, SWNTs behave as p-type semiconduc-
tors in ambient atmosphere. In p-type FETs, positive gate
voltage decreases the conductance (depletion) and negative
gate voltages increase the conductance (accumulation) from
the device. Therefore, if positively charged molecules bind
with probe molecules on SWNT-FETs, this event appears as
a decrease of conductance, while binding of negatively
charged molecules appears as an increase of conductance in
SWNT-FETs as denoted in Fig. 6.
Using FETs for immunosensing was first proposed by
Shenk [48] in 1978. It was suggested that FETs could be
used to detect surface polarization owing to the formation
of an antibody and an antigen. This concept failed,
however, because small ions in the solution caused a
screening effect inhibiting detection of the changes [49].
Figure 7 shows the charged semiconductor surface in
solution. As shown in Fig. 7, when a charged surface (this
might be a metal electrode, a semiconductor or a charged
dielectric) is brought into contact with an ionic solution, the
surface charge potential is dissipated by redistribution of
counter ions in the solution. The domains where the
Fig. 6 The working principle of field-effect transistor (FET) sensors
based on carbon nanotubes
Fig. 5 a Binding of coccaine with an MB-tagged aptamer. b Binding
of platelet-derived growth factor (PDGF) with an MB-tagged aptamer.
(a Reprinted with permission from [34], copyright 2006 American
Chemical Society; b reprinted with permission from [35], copyright
2007 American Chemical Society)
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variation of electric potential occurs are called electrical
double layers, and the depth of an electrical double layer can
be determined by calculating the Debye screening length.
The Debye screening length is the scale over which mobile
charge carriers screen the electric field. In an electrolyte, the



















and is 0.7 nm at standard pressure and temperature. kB is the
Boltzmann constant, k is defined as 1/4πɛ0, ρi is the number
density of ions and the zi values are valencies of various ions.
The Debye screening length, therefore, is proportional to
the inverse square root of the ion number density, i.e., to
ionic strength. For pure water, the Debye screening length
is about 1 μm, while it is only 0.3 nm in 1 M NaCl
solutions. In 1 M NaCl solution, therefore, two ions or
charged species separated by 1 nm do not interact with each
other. If we consider the sensor surface, any interactions
occurring outside the Debye screening length cannot be
detected using FET sensors. The biggest disadvantage of
FET sensors is that they may not work with blood samples
or body fluids, because the ionic strength of such
physiological solutions is about 150 mM, which yields a
Debye screening length of about 1 nm.
Until recently, FET-type sensors have employed an
antibody as the recognition receptor. However, the typical
size of an antibody is about 10–15 nm [50, 51]. In that case,
the binding of an antigen with an antibody occurs far outside
the Debye screening length in physiological solutions.
Molecular recognition elements with high specificity, selec-
tivity and small sizes are essential for applications of FET-
type sensors. In this respect, aptamers are highly suitable.
Figure 8 shows the typical size ranges of antibodies and
aptamers [52]. Because aptamers are mostly short nucleic
acids ranging from 10 to 60 bp in length, the binding of
target molecules with aptamers can occur inside the electrical
double layer, even in 20–50 mM salt solutions.
Such a biggest merit of aptamers in FET sensors was first
reported by So et al. [36] using a carbon nanotube biosensor
with thrombin aptamers as molecular recognition elements.
They also demonstrated the sensitivity and selectivity of
aptamers in SWNT-FETs. Anti-thrombin aptamers (5′-GGT
TGG TGT GGT TGG-NH2-3′) were immobilized onto the
surface of the SWNT-FET, fabricated using a patterned
growth technique, with carbonyl diimidazole–Tween 20 as
the linking molecules (Fig. 9a). The authors observed an
abrupt decrease in conductance upon reaction with thrombin,
while almost no changes were observed with elastase
(Fig. 9b). Elastase is a member of the thrombin family and
has almost the same molecular weight and isoelectric point
as thrombin. Moreover, the sensor could be regenerated by
simple washing with 6 M guanidine hydrochloride solution.
Fig. 8 Size comparison of an aptamer with an antibody. IgG
immunoglobulin G. (Reprinted from [52], copyright 2006 Elsevier)
Fig. 7 Electrical double layer at
the sensor surface
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The authors regenerated the sensor more than five times
without significant loss of activity. As shown in Fig. 9c, the
authors measured the sensitivities of SWNT-FET sensors
with aptamers as recognition elements. Before each mea-
surement, the sensor was "reset" by washing it with
guanidine hydrochloride solution. The lowest detection limit
was around 10 nM thrombin, and the sensor signal was
saturated at about 100 nM thrombin.
Maehashi et al. [37] have recently addressed the size
issue of recognition elements in FET-based sensors. In their
work, immunoglobulin E (IgE) aptamer (5′-NH2-GCG
CGG GGC ACG TTT ATC CGT CCC TCC TAG TGG
CGT GCC CCG CGC-3′) and monoclonal anti-IgE
antibody (IgE-mAb) were immobilized on carbon nanotubes,
with the aid of the linking molecule 1-pyrenebutanoic acid
succinimidyl ester. Figure 10 a and b shows the responses of
the aptamer-functionalized and antibody-functionalized sen-
sors, respectively, when they were exposed to known
concentrations of target IgE in 10 mM phosphate-buffered
saline (PBS). As shown in Fig. 10, the aptamer-functionalized
sensor exhibited small changes with only 250 pM target
protein molecules, while a negligible change in conductance
was observed in the antibody-funtionalized sensor even with
140 nM IgE. In 10 mM PBS, the Debye screening length
would be roughly 3 nm, and the binding of IgE with the
aptamer would be safely inside the electrical double layer.
Fig. 10 The sensor signal mea-




lin E, PBS phosphate-buffred
saline. (Reprinted with permis-
sion from [37], copyright 2007
American Chemical Society)
Fig. 9 a Single-walled carbon
nanotube (SWNT) FET sensor
with aptamers as molecular recog-
nition elements. b Selectivity
of an anti-thrombin aptamer-
functionalized SWNT-FET.
c Sensitivity of an anti-thrombin
aptamer-functionalized SWNT-
FET. The sensor was reset by
washing it with 6 M guanidine
hydrochloride solution before
each measurement. CDI carbonyl
diimidazole. (Reprinted with per-
mission from [36], copyright 2005
American Chemical Society)
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With IgE-mAb, however, there is little hope that binding can
be detected in the buffer solution used for the experiment,
because the antibody molecule is about 10 nm long [53].
As discussed, aptamers may allow a wider range of
analytes in FET sensors owing to their small size. SWNT-
FET sensors with aptamers as recognition elements showed
high sensitivity and selectivity, and could be readily regen-
erated. Highly sensitive carbon nanotube sensors combined
with small, economic, highly selective and stable aptamers
could provide cost-effective point-of-care testing devices.
Concluding remarks
This review has focused on the advantages of electrochem-
ical and FET sensor types with aptamers as recognition
elements. Through use of aptamers for recognition, no
labeling is required for electrochemical sensors, and signal-
on architecture that is only possible with aptamers has made
possible the sensitivity improvements. Also, as pointed out
already, sensors can be recycled because of the reversibility
of aptamer configurations. Alternatively, bound proteins
may be simply washed off, without damaging the aptamers.
In immunosensing, by contrast, it is practically impossible
to remove bound antigens from antibodies without damag-
ing the antibodies, because both antibodies and antigens are
proteins in nature. Aptamers have proved their superiority
over antibodies in nano-FET sensors. When no signal can
be measured with an antibody–antigen pair because of the
large size of the antibody, the binding of small aptamers to
various targets can occur inside the electrical double layer
where the nanotube can "feel" the change.
Owing to the rapid aging of society, there is great demand
for paradigm-breaking biosensors to detect the onset of
disease with speed, convenience and accuracy. In a few more
years, electrical nanosensors, with engineered aptamers, will
become prominent in the market. They will be small in size,
high in sensitivity and competitive in price.
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